Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RFA combined with ipilimumab for metastatic uveal melanoma to the liver
NL-OMON26122Phase 2Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Apr 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ipilimumab in intraocular melanoma, sponsored by Netherlands Cancer Institute. Primary endpoints: Dose-limiting toxicity and safety, Adverse events and 1 more. Started Apr 2012; status: active, not recruiting.
02
Drugs
ipilimumab
03
Conditions
intraocular melanoma
Beyond the preview
Go deeper on NL-OMON26122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON26122.